{"id":"NCT02926898","sponsor":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","briefTitle":"A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children â‰¥ 2 Years Old and Young Adults With Dravet Syndrome","officialTitle":"A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults With Dravet Syndrome (Cohort 2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-27","primaryCompletion":"2018-06-05","completion":"2018-06-05","firstPosted":"2016-10-06","resultsPosted":"2022-10-19","lastUpdate":"2022-11-02"},"enrollment":87,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dravet Syndrome"],"interventions":[{"type":"DRUG","name":"ZX008 (Fenfluramine Hydrochloride)","otherNames":[]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"Cohort 2: ZX008 0.5 mg/kg/day","type":"EXPERIMENTAL"},{"label":"Cohort 2: Matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of ZX008 (fenfluramine hydrochloride) when added to adjunctive antiepileptic stiripentol treatment in children and young adults with Dravet syndrome.","primaryOutcome":{"measure":"Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period","timeFrame":"15 weeks (combined Titration + Maintenance Period)","effectByArm":[{"arm":"Cohort 2: ZX008 0.5 mg/kg/Day","deltaMin":-3.18,"sd":44.121},{"arm":"Cohort 2: Matching Placebo","deltaMin":-0.65,"sd":8.767}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":28,"countries":["United States","Canada","France","Germany","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["31790543","34768178","33540241"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":43},"commonTop":["Decreased appetite","Nasopharyngitis","Pyrexia","Diarrhea","Fatigue"]}}